Dogra 1992

Methods	Study design: randomised controlled trial Setting/location: India Study period: not described Sample size calculation: not described
Participants	Type of Leishmania: L tropica in the area Inclusion criteria: participants with localised CL and only smear positive cases Exclusion criteria: not being smear positive N randomised: 60, 20 in each group Withdrawals: 0 N assessed: 60 (100%), 20 in each group Age (years): ≥ 15 years Sex: not described Severity of illness: 8, 11, and 12 participants had multiple lesions in the itraconazole, dapsone and placebo groups respectively.
Interventions	Type of interventions: Group 1: itraconazole 4 mg/kg/d (max. 200 mg) Group 2: dapsone 4 mg/kg in 2 doses/d Group 3: placebo control group Duration of intervention: 6 weeks Duration of follow‐up: 6 weeks, but 3 months for assessment of relapses
Outcomes	Healing rates: percentage of participants 'cured' at the end of treatment. Strict clinical and parasitological criteria were followed to asses cure. Adverse effects Time points reported: healing rates at the end of treatment
Notes	Study funding sources: none reported Possible conflicts of interest: none declared
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not described
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	Low risk	Relevant outcomes were reported
Other bias	High risk	Sample size calculation and reporting of Leishmania spp involved was not correctly reported